角膜神经化当前概念综述
角膜神经化(CN)通过移植健康供体轴突至无感觉角膜,重建传入神经支配,为上皮维持和视力康复创造条件。直接与间接技术均改善上皮愈合和眼表指标,但间接法感觉恢复更优。年轻和先天性病因感觉恢复更好,高龄和获得性病因视力改善更大。建议早期转诊并在视力丧失和不可逆基质损伤前干预。
要点
- CN通过移植供体轴突重建角膜感觉,直接解决神经营养性角膜病变的生物学缺陷。
- 间接法经神经移植感觉恢复优于直接法,但两者上皮愈合和Mackie分期改善相当。
- CN后角膜移植应推迟至CN后1年且角膜感觉超过30 mm、眼表稳定时进行。
核心结论
- CN在多个国际中心显示一致的有效性和安全性,应作为神经营养性角膜病变管理的核心原则,早期转诊并在视力丧失和不可逆基质损伤前干预。
研究设计与样本
- 本文为综述,回顾自Terzis于2009年首次描述直接手术CN以来的领域进展,包括微创技术、供体神经选择算法和结局比较。
主要发现
- 直接和间接技术均达到上皮愈合、眼表指标和Mackie分期的可比改善,但经神经移植的间接CN感觉恢复更优。
- Meta分析显示CN后角膜感觉有统计学显著改善,多数患者视力也获增益。
- 年轻和先天性病因与更大感觉恢复相关,高龄和获得性病因预测更大视力改善,可能反映小儿队列弱视的混杂效应。
- 脱细胞神经同种异体移植物消除供区并发症但缺乏施万细胞,与自体移植的头对头比较仍缺乏。
- 并发症谱低,供区后遗症通常轻微且自限,严重眼部并发症不常见。
关键数值与推荐
- 供体神经选择遵循基于感觉丧失模式的分级算法,首选同侧三叉神经分支,三叉神经感觉缺失时可用耳大神经。
- CN后角膜移植应推迟至CN后1年,且待角膜感觉超过30 mm、眼表稳定时进行。
临床怎么用
- 对神经营养性角膜病变应早期转诊,在视力丧失和不可逆基质损伤前考虑CN干预。
- 根据感觉丧失模式选择供体神经:同侧三叉神经分支优先,三叉神经感觉缺失时用耳大神经。
- CN后需等待1年且角膜感觉超过30 mm、眼表稳定后再行角膜移植。
局限性
- 脱细胞神经同种异体移植物与自体移植的头对头比较仍缺乏。
- 辅助神经营养治疗的当前证据有限。
- 需要多机构结局注册登记来强化证据基础并指导未来临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurotrophic keratopathy (NK) results from loss of trigeminal innervation to the cornea, disrupting epithelial integrity, tear film regulation, and ocular surface homeostasis. Conventional treatments address the surface consequences of denervation but do not restore sensory input. Corneal neurotization (CN) directly addresses this biological deficit by transferring healthy donor axons to the anesthetic cornea, re-establishing afferent innervation, and creating the conditions for epithelial maintenance and visual rehabilitation. Since Terzis first described direct surgical CN in 2009, the field has evolved considerably. Minimally invasive techniques using interpositional nerve grafts have broadened applicability to bilateral disease and patients without intact ipsilateral trigeminal sensation. Donor nerve selection follows a hierarchical algorithm based on the pattern of sensory loss, with ipsilateral trigeminal branches preferred, and the greater auricular nerve available when trigeminal sensation is absent. Both direct and indirect techniques achieve comparable improvements in epithelial healing, ocular surface metrics, and Mackie staging, though indirect CN via nerve grafting appears to yield superior sensory recovery. Acellular nerve allografts eliminate donor site morbidity but lack Schwann cells, and head-to-head comparisons with autografts remain lacking. Meta-analyses demonstrate statistically significant improvements in corneal sensation following CN, with the majority of patients also achieving gains in visual acuity. Younger age and congenital etiology are associated with greater sensory recovery, while older age and acquired etiology predict greater visual improvement, likely reflecting the confounding effects of amblyopia in pediatric cohorts. Keratoplasty post-CN can also be undertaken in eyes previously considered poor candidates, though surgery should be deferred for a year after CN and not until corneal sensation exceeds 30 mm with a stable ocular surface. The complication profile is low. Donor site sequelae are typically mild and self-limiting, and serious ocular complications are uncommon. Adjuvant neurotrophic therapy represents a potential future strategy for optimizing outcomes, with current evidence limited. Given the consistent efficacy and safety of CN across international centers, earlier referral of NK and intervention before visual loss and irreversible stromal injury should now be considered a central principle of NK management. A multi-institutional outcomes registry would strengthen the evidence base and guide future clinical decision-making.
引用
- Ashton C, Borschel GH, Mireskandari K, et al. Current Concepts in Corneal Neurotization. Am J Ophthalmol. 2026. PMID: 42285466. doi:10.1016/j.ajo.2026.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。